Moderna News - October 2026
Moderna Shares Plunge After Leak Shows 42% Cancer Risk Cut
Moderna shares fell more than 20% on Thursday after detailed results for its personalized melanoma vaccine, intismeran, developed with Merck, were apparently...
Moderna Drops 12% After a 700% Rally — Can a Single Data Readout Justify a $98 Billion Valuation?
Shares of Moderna plunged 11.9% to $216.65 on Thursday as investors locked in profits from a breathtaking cancer-vaccine rally, with the critical question now...
🔴 Moderna is trading 12% down today as investors reassess valuation before full trial data
Moderna is trading at $216.65 (-11.86%) as investors reassess its valuation after a sharp rally tied to positive Phase 3 melanoma-vaccine news. - Full data...
🟢 Moderna is trading 4.03% up today amid melanoma-vaccine optimism
Moderna is trading 4.03% higher at $251.84 on October 21 as investors focus on positive Phase 3 results for its personalized melanoma vaccine with Merck. - The...
🔴 Moderna is trading 10.3% down today amid biotech-sector selling
Moderna is trading at $212.16, down 10.29%, amid an active biotech-sector selloff. - XBI was down 2.06% during the regular session. - Citi’s recent Sell...
🟢 Moderna is trading 10% up today after Nasdaq-100 inclusion, with possible index-fund buying
Moderna is trading at $217.37, up 10.34%, with its Nasdaq-100 inclusion the clearest company-specific catalyst. - The inclusion took effect before the market...
Moderna's 8% Pop on Nasdaq-100 Inclusion: Can Passive Fund Buying Sustain a Stock That Has Struggled for Years?
Shares of Moderna surged 8.3% to $213.38 on October 9 as the biotech's addition to the Nasdaq-100 index took effect before the opening bell, forcing billions...
🟢 Moderna is trading 8% up today amid potential Nasdaq-100 fund buying
Moderna is trading 8.31% higher at $213.38, with Nasdaq-100 inclusion-related buying the clearest catalyst. - Nasdaq confirmed the addition, effective before...
Moderna Launches First mRNA Flu Vaccine, mFlusiva, for 2026–27 Season
Moderna’s first mRNA-based seasonal flu vaccine, mFlusiva, is now available in the U.S. for the 2026–2027 flu season. [4, 11] The FDA approved it in August...